Skip to main content icon/video/no-internet

By avoiding the difficult and uncomfortable issue of assigning monetary values to intangible health benefits, cost-effectiveness analysis (CEA) sacrifices the easy decision rule of cost-benefit analysis (CBA): An intervention or program represents an economically appropriate use of scarce resources if and only if the value of its health benefits exceeds its costs. Unfortunately, for the analyst preparing a CEA and the decision-maker faced with the findings from a CEA, the monetization of intangible health benefits by CEA can only be avoided in appearance. The decision maker must still wrestle with the value versus cost trade-off to interpret the results of the analysis. Therefore, the analyst also faces the dilemma of whether or not to provide the decision maker with guidance as to whether or not the intervention or program is worth its costs. That guidance often takes the form of a comparison of the incremental cost per health outcome achieved with a threshold value. This entry provides an overview of the key issues that analysts and decision makers should consider when using a threshold value (measured as cost per quality-adjusted life year [QALY]) to determine whether or not an intervention or program is cost-effective.

Theoretically Appropriate Threshold

The decision problem can be conceptualized as an attempt to maximize health benefits for a given cost. The implicit $/QALY is the shadow price on a QALY from this maximization, which represents the opportunity cost of the resources devoted to producing an additional QALY (technically speaking, the shadow price is the value of the Lagrange multiplier on the budget constraint). Hence, the threshold depends on any parameter of the decision context that affects the objective function or the constraints. Examples of factors that would affect the optimal threshold include the nature of the decision maker's utility function (e.g., extent of risk aversion), the position on utility function (how many other programs already funded), the available budget, and the discount rate. In addition to these factors, some research implies that the willingness to pay may be higher when the condition being treated is life threatening versus a condition that impairs only quality of life or that social willingness to pay for health benefits may differ by characteristics of the beneficiary such as age. This suggests that the basic premise that “a QALY is a QALY” may not be valid in some contexts, which would further require different thresholds based on the type of condition being treated.

The many determinants of the optimal threshold value should give the analyst and decision maker pause in adopting a “generic” threshold that is not attuned to their specific context. However, without appealing to a generic threshold, the decision maker would be left with little of a framework on which to make necessary adjustments. Similarly, the analyst is often writing for an unknown client with an unknown context (e.g., when publishing a CEA in the peer-reviewed literature). Therefore, the analyst's desire to conclude with a generic recommendation is also understandable.

Common Generic Thresholds

Rules of Thumb

Given the psychological predilection for round numbers, it should come as no surprise that rules of thumb (ROTs) such as $50,000 or $100,000 per QALY are among the most common thresholds proposed in CEA studies. The most often used threshold appears to be $50,000 per QALY. The origin of the $50,000 threshold is, in part, that it approximated U.S. spending per renal dialysis patient year more than 20 years ago. Given the legislative decision to cover care for kidney failure patients by providing them with an entitlement to Medicare, it has been argued that other care with comparable or better cost-effectiveness should also be covered. However, note that this “dialysis standard” is based on an approximation of $50,000 per life year; the implied $/QALY threshold would actually be considerably higher, given that dialysis patients' quality-of-life scores are well below 1.0. Furthermore, under the reasoning that care for dialysis patients is worth its cost, that would imply the $50,000 threshold is a floor for a reasonable threshold, not a ceiling.

...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles

Sage Recommends

We found other relevant content for you on other Sage platforms.

Loading